Study of KN057 for hemophilia A or B with or without inhibitors
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests a new drug called KN057 for people with severe hemophilia A or moderate-to-severe hemophilia B, whether or not they have developed inhibitors (antibodies that block standard treatments). The goal is to see if it can help prevent or treat bleeding episodes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are male and between 18 and 70 years old.
- You have severe hemophilia A or moderate-to-severe hemophilia B (with factor VIII activity below 1% or factor IX activity at or below 2%).
- You have had at least 6 treated bleeding episodes in the past 6 months (not counting bleeds from surgery).
- If you have no inhibitors, you must have had more than 100 days of factor replacement therapy and test negative for inhibitors now.
- If you have inhibitors, your inhibitor level must be high (≥5 BU/mL) or low but still not responding to factor, with a poor recovery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether KN057, a new preventive medicine, is safe for males with hemophilia A or B. It aims to help prevent bleeding episodes without causing unwanted blood clots.
This study tests a new medicine called NXT007 for people with hemophilia A. It compares NXT007 to standard factor VIII treatment to see if it works better at preventing bleeding episodes.
This trial tests a new factor VIII treatment (SKP-0141) for severe hemophilia A. It aims to see if it can prevent or treat bleeding episodes, replacing standard factor VIII therapy.
This trial tests a new injection called GS1191-0445 for people with hemophilia A. It aims to see if it is safe and works well to prevent or treat bleeding episodes.
This trial tests a single dose of ANB-002, an experimental therapy for hemophilia B. It aims to see if the drug is safe and effective for people with severe hemophilia B who have been treated with factor IX before and do not have inhibitors.
This trial tests a new medicine called NXT007 to see if it is safe and effective for people with severe or moderate hemophilia A, including those with inhibitors. It may help reduce bleeding episodes.
Hear when a new Hemophilia a and B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.